专题：Diabetes Treatment and Management

This cluster of papers focuses on the management of diabetes mellitus, with a particular emphasis on cardiovascular outcomes, glucose control, and the use of incretin hormones, SGLT2 inhibitors, and dipeptidyl peptidase-4 inhibitors. It also covers topics such as heart failure, glycemic control, insulin therapy, and clinical guidelines for the treatment of type 2 diabetes.
最新文献
Efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population.

article Full Text OpenAlex

Cardiovascular–kidney–metabolic syndrome and all-cause and cardiovascular mortality: A retrospective cohort study

article Full Text OpenAlex

Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide

article Full Text OpenAlex

Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial

article Full Text OpenAlex

Understanding the drivers and consequences of early-onset type 2 diabetes

review Full Text OpenAlex

Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

article Full Text OpenAlex

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity

article Full Text OpenAlex

Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial

article Full Text OpenAlex

Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial

article Full Text OpenAlex

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial

article Full Text OpenAlex

近5年高被引文献
Empagliflozin in Heart Failure with a Preserved Ejection Fraction

article Full Text OpenAlex 3576 FWCI536.601

Once-Weekly Semaglutide in Adults with Overweight or Obesity

article Full Text OpenAlex 3051 FWCI400.403

Tirzepatide Once Weekly for the Treatment of Obesity

article Full Text OpenAlex 2107 FWCI351.252

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

article Full Text OpenAlex 1906 FWCI363.298

Empagliflozin in Patients with Chronic Kidney Disease

article Full Text OpenAlex 1640 FWCI312.76

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

article Full Text OpenAlex 1469 FWCI450.661

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

review Full Text OpenAlex 1365 FWCI61.663

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

article Full Text OpenAlex 1310 FWCI177.146

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

article Full Text OpenAlex 1292 FWCI418.489

Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure

article Full Text OpenAlex 1206 FWCI163.243